Programme |
SKYCovione |
Therapeutic area/Indication |
Covid-19 |
Partner |
SK bioscience |
Status |
Approved |
Programme |
EVT201 |
Therapeutic area/Indication |
CNS - Insomnia (GABA-A) |
Partner |
JingXin |
Status |
Phase III |
Programme |
CT7001 |
Therapeutic area/Indication |
Oncology (CDK7) |
Partner |
Carrick |
Status |
Phase II |
Programme |
TPM502 |
Therapeutic area/Indication |
Celiac Disease (ND) |
Partner |
Topas Therapeutics |
Status |
Phase IIa |
Programme |
EVT401 |
Therapeutic area/Indication |
Immunology & Inflammation (P2X7) |
Partner |
CONBA Group |
Status |
Phase I |
Programme |
TPM203 |
Therapeutic area/Indication |
Pemphigus Vulgaris (ND) |
Partner |
Topas Therapeutics |
Status |
Phase I |
Programme |
CNTX 6016 |
Therapeutic area/Indication |
Pain (CB2) |
Partner |
Centrexion |
Status |
Phase I |
Programme |
EVT894 |
Therapeutic area/Indication |
Chikungunya (ND) |
Partner |
Sanofi/NIH |
Status |
Phase I |
Programme |
EXS21546 |
Therapeutic area/Indication |
Oncology (A2a) |
Partner |
Exscientia |
Status |
Phase I/II |
Programme |
EVT801 |
Therapeutic area/Indication |
Oncology (VEGFR3) |
Partner |
Kazia Therapeutics |
Status |
Phase I |
Programme |
BMS-986419 / EVT8683 |
Therapeutic area/Indication |
Neurodegeneration (elF2b) |
Partner |
Bristol Myers Squibb |
Status |
Phase I |
Programme |
IMT-009 |
Therapeutic area/Indication |
Oncology (CD161) |
Partner |
Immunitas |
Status |
Phase I |
Programme |
BAY3401016 |
Therapeutic area/Indication |
Alport Syndrome (Sema3A) |
Partner |
Bayer |
Status |
Phase I |
Programme |
Encaps-iBeta |
Therapeutic area/Indication |
Diabetes - beta cell replacement therapy |
Partner |
Sernova |
Status |
Pre-clinical |
Programme |
EVT075 |
Therapeutic area/Indication |
Covid-19/ HBV (ND) |
Partner |
Currently unpartnered |
Status |
Pre-clinical |
Programme |
Various |
Therapeutic area/Indication |
CNS, Metabolic, Pain ...... |
Partner |
>10 further programmes |
Status |
Pre-clinical |
Programme |
Various |
Therapeutic area/Indication |
Neurodegeneration |
Partner |
Bristol Myers Squibb |
Status |
Discovery |
Programme |
Various |
Therapeutic area/Indication |
Oncology - solid tumours |
Partner |
Bristol Myers Squibb |
Status |
Discovery |
Programme |
Various |
Therapeutic area/Indication |
Immunology & Inflammation - Tissue Fibrosis |
Partner |
Pfizer |
Status |
Discovery |
Programme |
Various |
Therapeutic area/Indication |
Nephrology |
Partner |
Novo Nordisk |
Status |
Discovery |
Programme |
Various |
Therapeutic area/Indication |
Nephrology |
Partner |
Chinook Therapeutics |
Status |
Discovery |
Programme |
Various |
Therapeutic area/Indication |
Various |
Partner |
Takeda |
Status |
Discovery |
Programme |
ND |
Therapeutic area/Indication |
Oncology |
Partner |
Breakpoint Therapeutics |
Status |
Discovery |
Programme |
ND |
Therapeutic area/Indication |
Anti-infectives |
Partner |
Blacksmith |
Status |
Discovery |
Programme |
INDY inhibitor |
Therapeutic area/Indication |
Metabolic |
Partner |
Eternygen |
Status |
Discovery |
Programme |
ND |
Therapeutic area/Indication |
Fibrotic disease |
Partner |
Fibrocor |
Status |
Discovery |
Programme |
ND |
Therapeutic area/Indication |
Gaucher |
Partner |
Centogene |
Status |
Discovery |
Programme |
Various |
Therapeutic area/Indication |
Various |
Partner |
Topas Therapeutics |
Status |
Discovery |
Programme |
ND |
Therapeutic area/Indication |
Heart failure |
Partner |
UKE |
Status |
Discovery |
Programme |
Various |
Therapeutic area/Indication |
Various |
Partner |
LAB282 / LAB150 / Autobahn Labs / beLAB2122 / beLAB1407 / Danube Labs |
Status |
Discovery |
Programme |
Various |
Therapeutic area/Indication |
Anti-infectives |
Partner |
>5 programmes |
Status |
Discovery |
Programme |
Various |
Therapeutic area/Indication |
Internal: Oncology, CNS, Metabolic, Pain & Inflammtion, Immunology and Anti-invectives |
Partner |
>40 further programmes |
Status |
Discovery |